131 related articles for article (PubMed ID: 17410461)
1. Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?
Shimatani T; Kuroiwa T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Dis Sci; 2007 Oct; 52(10):2826-32. PubMed ID: 17410461
[TBL] [Abstract][Full Text] [Related]
2. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
3. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
4. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
5. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
[TBL] [Abstract][Full Text] [Related]
6. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Shimatani T; Inoue M; Kuroiwa T; Horikawa Y
Aliment Pharmacol Ther; 2004 Jan; 19(1):113-22. PubMed ID: 14687173
[TBL] [Abstract][Full Text] [Related]
7. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
11. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
[TBL] [Abstract][Full Text] [Related]
12. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
14. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
[TBL] [Abstract][Full Text] [Related]
15. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Shimatani T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Liver Dis; 2006 Nov; 38(11):802-8. PubMed ID: 16843075
[TBL] [Abstract][Full Text] [Related]
16. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist.
Shimatani T; Inoue M; Kuroiwa T; Horikawa Y; Mieno H; Nakamura M
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1149-57. PubMed ID: 14653835
[TBL] [Abstract][Full Text] [Related]
17. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
18. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
